Comparing liver fat and blood markers in people with obesity after bariatric surgery
Compares liver fat and blood markers in adults with obesity having surgery or other treatment.
Plain-language title generated from the registry record
Registry title: Bariatric Surgery for Obesity
Key facts
- Where
- Asyut, EgyptSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity (BMI of 30 or more). One group is having sleeve gastrectomy or gastric bypass surgery. The other group is managed with diet and lifestyle changes.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Obesity with a BMI of 30 or more.
- Earlier treatment
- Cannot have had bariatric surgery before. Cannot have used antibiotics or probiotics in the past 3 months.
Main reasons for not taking part
- Earlier bariatric surgery
- Inflammatory bowel disease
- Antibiotic or probiotic use in the past 3 months
- Severe liver dysfunction
- Severe kidney dysfunction
Read by machine on 12 November 2026.
Where in Egypt
- Assiut university HospitalsAsyut, EgyptContact: Ahmed Elsayed AbdallahNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Assiut University
- Trial code
- NCT06901440
- Record updated
- 30 March 2025
- Original description
Obesity has reached pandemic proportions worldwide, and its increased prevalence is associated with a plethora of metabolic disturbances. The obese state is characterized by increased adipose tissue mass and disturbed function resulting in systemic lipid spillover and low-grade inflammation, which may contribute to the development of comorbidities such as type 2 diabetes mellitus (T2DM) and cardiovascular disease. The crosstalk between various metabolic organs such as the gut, liver, adipose tissue, and skeletal muscle plays an important regulatory role in energy and substrate metabolism, which impacts metabolic health. The studies on the gut microbiota in host energy and substrate metabolism, \& its relation to Obesity are neumerous, includes interventions that modify the gut microbiota composition and functionality with antibiotics , prebiotics \& probiotics .Read full original descriptionShow less
Metabolic Biomarkers and Clinical Outcomes in Obesity: a Comparative Study of Surgical and Non-Surgical Cohorts
Obesity has reached pandemic proportions worldwide, and its increased prevalence is associated with a plethora of metabolic disturbances. The obese state is characterized by increased adipose tissue mass and disturbed function resulting in systemic lipid spillover and low-grade inflammation, which may contribute to the development of comorbidities such as type 2 diabetes mellitus (T2DM) and cardiovascular disease. The crosstalk between various metabolic organs such as the gut, liver, adipose tissue, and skeletal muscle plays an important regulatory role in energy and substrate metabolism, which impacts metabolic health. The studies on the gut microbiota in host energy and substrate metabolism, \& its relation to Obesity are neumerous, includes interventions that modify the gut microbiota composition and functionality with antibiotics , prebiotics \& probiotics .
Obesity-associated with metabolic conditions such as ( Non alcoholic fatty liver diseases )NAFLD.
Obesity-associated NAFLD includes a spectrum of histological abnormalities ranging from steatosis to the inflammatory form of NAFLD, known as NASH. It is frequently seen in severe obesity, and its prevalence has been found to increase up to 90% in such patients in some countries.
So, in this study we compare liver status regarding degree of Steatosis among different patients, using Serum Biomarkers Scores and imaging techniques in obese patients undergo bariatric surgery ( case group ), and obese patients taking other lines of treatment ( Control group ); to detect if Bariatric surgery has better outcome for Steatosis and inflammatory markers than other lines of management for obesity.
- Research outcome measures:
a. Primary (main):
* Compare liver status regarding steatosis using Serum Biomarkers Scores in obese patients undergo bariatric surgery and obese patients taking other lines of treatment. * Correlate these changes with weight loss and glycemic control. * Secondary (subsidiary): * Evaluate associations between these scores and insulin resistance, lipid profiles and inflammatory markers.
Inclusion: Two groups:; Intervention group: 25 adults (BMI ≥30) undergoing sleeve gastrectomy or Roux-en-Y gastric bypass; Control group: 25 adults (BMI ≥30) managed with lifestyle/ dietary interventions.
Exclusion: Prior bariatric surgery, inflammatory bowel disease, antibiotic/probiotic use (past 3 months), or severe hepatic/renal dysfunction.